|  | Company-Sponsored by OKYO Pharma* | TODAY'S TOP ALERT! | Nasdaq: OKYO | | Hey Folks, | Just a brief update on an urgent situation… | It's looking like the markets may extend yesterday's losses this session, and there's not a whole lot in the green. | That is, unless you are following my "tactical trade" of the day. | I wrote to you this morning (all before the market even opened!) about a small biotech that was on the move yesterday even in that bloody market. | I thought "we could see more great action" and that it could be "today's big breakout story." | I'd say this qualifies: | | There still seems to be a lot of profit-taking going on, but zooming out, it's clear OKYO has broken through recent resistance and the stock has gone parabolic over the last couple of weeks: | | When I alerted OKYO back in October, we saw a very similar situation unfold, and the result was a 30% intraday gain, so we could still see considerable upside from here. | Of course, always be prepared for things to go against you when it comes to this market. Things can turn very fast right now. | If you caught my dispatch this morning, you know there's great reason for optimism… | The company is advancing OK-101 through two Phase 2 clinical trials, including for neuropathic corneal pain (NCP), a condition for which "there are no approved commercial treatments currently available." [emphasis added] | In the world of clinical-stage biotechs, this means the company is sitting on a potential goldmine. | There's no guarantee how the trials will work out, but early results are promising and OKYO executive chairman Gabriele Cerrone has scooped up more than 600,000 shares since September. | Does he know something investors don't (yet)? | On top of that, the sole analyst following the company has placed a 12-month price target of $7.00 on the stock — still more than 400% higher than its current trading price. | OKYO is clearly on the move, and this is an urgent situation that is worth watching. | For further research, I recommend starting with the company's website and its corporate presentation. | But whatever you do… | Don't let OKYO slip off your radar today! | To Your Success, | | | | Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull | | | *Issuer-paid advertisement: Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call "typical." | Just a quick heads up about this ad you're reading—as we've said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we have been paid twenty five thousand dollars (cash) by bank transfer by OKYO Pharma Limited for advertising for a one day marketing program on January 8, 2025. Previously, we also received paid twenty five thousand dollars (cash) by bank transfer by OKYO Pharma Limited for advertising for a one day marketing program on October 23, 2024. Be aware that we may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case. | Now, diving right into OKYO Pharma Limited might sound exciting. But remember, it's like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you're doing. That's why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. | Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We're simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We're obviously biased in our writing. We're not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as "forward-L00king statements" under the securities acts, so take those with a grain of salt. As with all forecasts, they're not set in stone, often wrong, and we certainly can't know where the Company's earnings, business, or share price will be tomorrow or a year from now. | Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, | Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep's with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization. | So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. |
|
Tidak ada komentar:
Posting Komentar